Skip to Main Content

Paper Details

Autophagy-associated immune dysregulation and hyperplasia in a patient with compound heterozygous mutations in <i>ATG9A</i>.
Autophagy
4
2023
BCL10, BCL10 immune signaling adaptor, BCL2, BCL2 apoptosis regulator, CARD11, CBM, CR2, EBNA, EBV, Epstein Barr nuclear antigen, Epstein-Barr virus, FCGR3A, Fc gamma receptor IIIa, GLILD, IKB kinase, IKBKB, IL2RA, MALT1, MALT1 paracaspase, MS4A1, MTOR, MYC, NCAM1, NFKB, NK, PBMCs, PTPRC, SELL, T cell receptor, Tregs, bHLH, caspase recruitment domain family member 11, complement C3d receptor 2, granulomatous-lymphocytic interstitial lung disease, hyperplasia, immune dysregulation, inhibitor of nuclear factor kappa B kinase subunit beta, interleukin 2 receptor subunit alpha, mechanistic target of rapamycin kinase, membrane spanning 4-domain A1, natural killer, neural cell adhesion molecule 1, nuclear factor kappa B, oncogene, patient, peripheral blood mononuclear cells, protein tyrosine phosphatase receptor type C, rapamycin, regulatory T cells, selectin L, tyrosine
Author NameAffiliation
Stefania PittalugaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Stefania PittalugaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Mark RaffeldNIH Clinical Center
Mark RaffeldNIH Clinical Center
Sergio D RosenzweigNIH Clinical Center
  • 1 - 5

Datasets